Imatinib augments standard malaria combination therapy without added toxicity

Area of Science:

• Malariology
• Pharmacology
• Infectious Diseases

Background:

• Plasmodium falciparum malaria requires erythrocyte membrane destabilization via tyrosine kinase activation for parasite egress.
• Imatinib is an inhibitor of tyrosine kinases with a known safety profile.

Purpose of the Study:

• To evaluate the safety and efficacy of combining imatinib with standard of care (SOC) for treating uncomplicated Plasmodium falciparum malaria.
• To determine if this combination therapy can prevent delayed parasite clearance (DPC).

Main Methods:

• A clinical trial involving patients with uncomplicated P. falciparum malaria in Vietnam.
• Participants received either SOC alone or imatinib plus SOC for 3 days.
• Adverse events, parasite density, and fever (pyrexia) were monitored.

Main Results:

• The imatinib + SOC group showed no increase in adverse events compared to SOC alone.
• Imatinib + SOC significantly accelerated parasite density decline and reduced fever.
• Delayed parasite clearance (DPC) was completely prevented in the imatinib + SOC group.
• Benefits were most significant in patients with initially high parasite densities.

Conclusions:

• Coadministration of imatinib with standard malaria therapy is well-tolerated and enhances therapeutic efficacy.
• Imatinib appears to be a promising adjunct therapy for improving outcomes in Plasmodium falciparum malaria, particularly in preventing DPC.